1. 1414PPrediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model. (23rd October 2018) Authors: Wakelee, H; Aredo, J; Vali, S; Singh, N K; Vasista, S V; Mitra, U; Abbasi, T; Padda, S K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Wakelee, H; Reckamp, K L; Leal, T A; Patel, S P; Blumenschein, G; Shum, E; Nieva, J; Oxnard, G; Sanborn, R E; Waqar, S; Zeman, K; Dukart, G; Harrow, K; Liang, C; Holzhausen, A; Horn, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1500TiPeXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. (23rd October 2018) Authors: Horn, L; Wu, Y-L; Reck, M; Wakelee, H; Liang, C; Harrow, K; Oertel, V; Mok, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. (15th December 2019) Authors: Drakaki, A; Luhn, P; Wakelee, H; Dhillon, P K; Kent, M; Shim, J; Degaonkar, V; Hoang, T; McNally, V; Chui, S Y; Gutzmer, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. (24th May 2019) Authors: Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. (14th June 2018) Authors: Bonomi, P D; Gandara, D; Hirsch, F R; Kerr, K M; Obasaju, C; Paz-Ares, L; Bellomo, C; Bradley, J D; Bunn Jr, P A; Culligan, M; Jett, J R; Kim, E S; Langer, C J; Natale, R B; Novello, S; Pérol, M; Ramalingam, S S; Reck, M; Reynolds, C H; Smit, E F Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗